Raymond James & Associates Corbus Pharmaceuticals Holdings, Inc. Transaction History

Raymond James & Associates

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$1.39 - $2.21 $24,576 - $39,075	-17,681 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$0.94 - $1.89 $22,481 - $45,203	-23,917 Reduced 57.5%	17,681 $22,000
Q3 2020 Nov 04, 2020	SELL	$1.5 - $9.38 $23,250 - $145,390	-15,500 Reduced 27.15%	41,598 $75,000
Q2 2020 Jul 28, 2020	BUY	$4.79 - $8.39 $83,825 - $146,825	17,500 Added 44.19%	57,098 $479,000
Q1 2020 Apr 21, 2020	SELL	$3.44 - $7.21 $75,680 - $158,620	-22,000 Reduced 35.72%	39,598 $207,000
Q4 2019 Feb 12, 2020	SELL	$4.29 - $5.64 $13,728 - $18,048	-3,200 Reduced 4.94%	61,598 $336,000
Q3 2019 Nov 07, 2019	SELL	$4.87 - $7.08 $87,786 - $127,624	-18,026 Reduced 21.76%	64,798 $316,000
Q2 2019 Aug 06, 2019	BUY	$6.6 - $7.8 $107,217 - $126,711	16,245 Added 24.4%	82,824 $574,000
Q1 2019 May 06, 2019	SELL	$5.76 - $8.95 $57,110 - $88,739	-9,915 Reduced 12.96%	66,579 $463,000
Q4 2018 Feb 11, 2019	BUY	$5.26 - $7.97 $183,842 - $278,559	34,951 Added 84.13%	76,494 $447,000
Q3 2018 Nov 14, 2018	BUY	$4.65 - $7.95 $106,694 - $182,412	22,945 Added 123.37%	41,543 $314,000
Q2 2018 Aug 14, 2018	BUY	$5.05 - $6.8 $13,700 - $18,448	2,713 Added 17.08%	18,598 $94,000
Q1 2018 May 14, 2018	BUY	$5.6 - $9.25 $88,956 - $146,936	15,885 New	15,885 $97,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.